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Abstract
The main risk factors for the development and progression of diabetic retinopathy (DR) are
chronic hyperglycemia, disease duration and systemic blood pressure. So far chronic hyperglycemia
is the strongest evidence concerning the risk of developing DR. However there are some patients
with poor metabolic control who never develop this diabetic complication. We present a case of
a 73-year-old woman with type 1 diabetes mellitus, diagnosed 69 years ago. The patient is 73 years
old, with no evidence of DR, despite poor glycemic control and several risk factors for DR. This
case suggests the presence of a possible protection factor, which could be genetic.
Introduction
Diabetic retinopathy (DR) is the main cause of blindness
in individuals aged 20-64 years, and accounts for 7.5% of
the causes of adult work disability in Brazil. The risk of
blindness is approximately 30-fold higher in people with
diabetes mellitus (DM), compared to the population in
general [1,2].
The most important risk factors for the development and
progression of DR are chronic hyperglycemia, duration of
the DM and systemic blood pressure levels [3-9]. Other
possible risk factors are dyslipidemia, pregnancy, puberty
and local ocular factors such as prior cataract surgery
(facectomy) [10].
So far the most solid evidence for the risk of developing
DR is chronic hyperglycemia [10-13]. After 20 years dura-
tion, there is some degree of DR in almost all patients with
type 1 DM, 20% of them severe [14]. In insulin users with
type 2 DM, the presence of DR occurs in approximately
84.5% of patients after 15 years of the disease [15].
However, there is great variability in the incidence of DR
among patients with DM, and therefore it must be asked
why some patients with poor metabolic control remain
free of this complication.
We present the case of a 73-year old woman who has had
type 1 DM for 69 years, without any evidence of DR,
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despite inadequate glycemic control and several other risk
factors for DR.
Case Report
White woman, 73 yrs old, nulliparous, type 1 DM diag-
nosed at age of 4 yrs, hypertension and dyslipidemia since
the age of 44, and diagnosis of hypothyroidism since the
age of 40. She smoked 20 cigarettes/day for 37 years. She
has used insulin since diagnosis, currently associated with
captopril 100 mg/day, simvastatin 40 mg/day, acetylsali-
cylic acid 200 mg/day and levotiroxine 75 μg/day, and has
been regularly followed at the Endocrine Service and
Ophthalmology Service at Hospital de Clínicas de Porto
Alegre for the last 20 years. Since then, she has maintained
inadequate glycemic control with recent mean HbA1c of
9.5% (reference values: 4 - 6.0%). During the follow up
period the HbA1c measurement methods were changed at
the hospital, and therefore figure 1A presents the values of
HbA1c in percentage points above the upper limit of nor-
mality of the technique used, showing that the patient
remained constantly above the target value. At physical
examination during this period, she has had a mean
blood pressure, of 124/84 mm Hg (Figure 1B) and main-
tains a body mass index of 24.2 kg/m2. She informed that
23 years ago she had a myocardial infarction (confirmed
by a fixed hypoperfusion area in the anterior wall of the
myocardium at scintigraphy with dipyramidol), and 4
years ago she was submitted to peripheral artery revascu-
larization surgery (aortofemoral bypass) and amputation
of the second toe of the left foot. The latest evaluation of
excretion of urinary albumin was 56.6 mg/24 hours (ref-
erence value <30 mg/24 hours).
At ophthalmologic examination, a visual acuity of 20/20
J1 was found in both eyes with the best correction. At
biomicroscopy of the anterior segment pseudofascia were
found in both eyes, with an ophthalmological history of
surgery of the cataract in the right eye on June 19, 2002
(extracapsular facectomy) and in the left eye on January
24, 2006 (facoemulsification with intraocular lens
implant). Measurement of intraocular pressure (IOP) was
performed, always within the limits of normality, with a
mean IOP of 14 mmHG in both eyes. At fundus examina-
tion of the eye, there was absence of signs of DR (Figure
2). The angiographic examination was also normal (Fig-
ure 3).
Discussion
The case shows the absence of DR in a patient with long
duration DM, inadequate glycemic control, hypertension
with irregular control and significant macrovascular dis-
ease.
Among the risk factors for the development of DM,
chronic hyperglycemia and hypertension are the factors
with the most solid evidence [1,2,16,17]. In the Wiscon-
sin Epidemiologic Study of Diabetic Retinopathy
(WESDR), the initial values of HbA1c were the most
important risk factor for the onset and progression of DR
[18,19]. Furthermore, hypertension is an important risk
factor for the onset and progression of the disease, and in
most studies it is an independent risk factor for DR.
The case reported illustrates that, despite the long dura-
tion of the disease, a few patients may not develop DR.
Besides the duration of DM, age at diagnosis of type 1 DM
appears to be related to the presence and severity of DR.
Harvey et al observed a greater need for laser therapy in
patients with a diagnosis of DM prior to the age of 15
years, and data from the EURODIAB suggest that the pre-
pubertal duration of DM is related to the onset of microv-
ascular complications[20,21]. The patient reported with
the type 1 DM, besides long duration of the disease pre-
Patient's long-term glycemic and blood pressure control Figure 1
Patient's long-term glycemic and blood pressure control. A. Evolution of the HbA1c test during the years of follow up 
(in percentage points above the higher limit of the reference). B. Evolution of the control of blood pressure (systolic and 
diastolic) during the years of follow up compared to the values advocated.Diabetology & Metabolic Syndrome 2009, 1:13 http://www.dmsjournal.com/content/1/1/13
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sented an early diagnosis, which would further increase
the risk of retinal injury.
The role of chronic hyperglycemia in the development of
DR has been well established. Maintaining high levels in
the HbA1c test is closely related to the development of
DR. The accumulated incidence of DR 10 years after type
1 DM has been diagnosed is approximately 90% in
patients with HbA1c between 10.2% and 11.5% [22].
Data from WESRD in type 1 DM demonstrate that for
every 1% increment in the HbA1c test values, the risk of
DR progression increases 1.21 fold [18,19]. The Diabetes
Control and Complications Trial (DCCT) and United
Kingdom Prospective Study (UKPDS) are randomized
clinical trials that demonstrate the efficacy of glycemic
control to prevent DR in patients with type 1 and type 2
DM, respectively [3,23]. Every 1% drop in the HbA1c test
leads to an estimated reduction of 30% in the risk of
microvascular complications [3,23].
The pressure levels also play an essential role in the patho-
genesis of DR, increasing intraluminal pressure and wors-
ening the blood-retinal barrier rupture [5-9]. In the
WESRD study, diastolic pressure was associated with the
presence of any degree of DR in patients with type 1 DM,
and it is an independent risk factor for progression to pro-
liferative DR [18,19]. The UKPDS demonstrated that
blood pressure control is associated with the reduction of
the DR incidence, and the relative risk of DR is 1.5 for
systolic BP between 125-139 and 2.8 for systolic BP >140
mm Hg [23].
The presence of DR is associated with cardiovascular mor-
tality both in patients with type 1 DM and in those with
type 2 DM. The more severe DR forms being associated
with a worse cardiovascular outcome. This evidence sug-
gests that microvascular disease precedes macrovascular
disease in a spectrum of a same disease triggered by
chronic hyperglycemia, systemic hypertension, dyslipi-
demia and obesity [11,24].
Even with unequivocal evidence of the role of the risk fac-
tors cited previously, in the development of DR, a few as
yet unidentified factors appear to counter this, protecting
a few individuals from this complication. In the DCCT,
approximately 40% of the patients with type 1 DM, with-
out DR at the beginning of the study and HbA1c >9.8%
did not present evidence of DR in 10 years of follow up
[3].
The clinical course of DR is an example of the effect of the
environmental component, in this case hyperglycemia, in
the onset of the disease. On the other hand, proliferative
DR, the most serious form of DR, affects individuals pro-
gressively, reaching a plateau after 20 years of DM. More-
over, intensive control of risk factors does not prevent the
development of DR in all the patients [24]. In addition, a
few ethnic groups have a higher frequency of DR. His-
panic and African-American patients present greater evi-
dence of DR compared to Caucasian patients. We
observed a higher proportion of sever DR among black
Brazilian subjects compared to whites [25]. These obser-
Eye fundus photograph showing the absence of diabetic retin- opathy Figure 2
Eye fundus photograph showing the absence of dia-
betic retinopathy. A - Right eye B - Left eye.
Study of normal angiofluoresceinography Figure 3
Study of normal angiofluoresceinography.Diabetology & Metabolic Syndrome 2009, 1:13 http://www.dmsjournal.com/content/1/1/13
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vations suggest that genetically susceptible patients will
develop DR more frequently. Studies of twin siblings with
type 2 DM present a concordance for a 95% presence of
DR. In patients with type 1 DM, the concordance is lower
(67.7%). In both situations, this concordance is much
higher than that expected from chance, suggesting a
genetic component, and that this is more important in
patients with type 2 DM. Studies of non-twin siblings
showed that the presence of proliferative DR in one
brother with type 2 DM increases the risk for the presence
of proliferative DR in his brother with DM around three-
fold. In the currently very fashionable studies on candi-
date genes, the associations of given genetic variants
called genetic polymorphisms, with the presence of DR
are evaluated. For instance, the genes of aldose reductase,
RAGE, VEGF, ACE, NOS, ICAM-1 and PPAR-δ have been
considered candidates for DR. A great diversity of results
is observed among these genetic studies, with positive and
negative associations with DR [2,26-31].
The case reported presents a woman who had had unsat-
isfactory glycemic control for a long time, hypertension
with recent regular control, and severe macroangiopathy
manifested by peripheral vasculopathy and cardiovascular
disease, without any retinal involvement. This suggests
that so far not all factors involved in the pathogenesis of
the retinal injury in DM have been identified. More
important, they call attention to the existence of locally
protective, possibly genetic factor. The identification of
this or these factors will enable a better understanding of
the pathogenesis of DR and the institution of specific
measures for the prevention and treatment of this compli-
cation of DM.
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